Elsevier

The Lancet

Volume 342, Issue 8882, 20 November 1993, Pages 1255-1262
The Lancet

Articles
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke

https://doi.org/10.1016/0140-6736(93)92358-ZGet rights and content

Abstract

Several studies have established the value of anticoagulation for primary prevention of thromboembolic events in patients with non-rheumatic atrial fibrillation (NRAF). However, in patients with a recent transient ischaemic attack (TIA) or minor ischaemic stroke the preventive benefit of anticoagulation or aspirin remains unclear. Physicians in 108 centres from 13 countries collaborated to study this question. 1007 NRAF patients with a recent TIA or minor ischaemic stroke were randomised to open anticoagulation or double-blind treatment with either 300 mg aspirin per day or placebo (group 1, 669). Patients with contraindications to anticoagulation were randomised to receive aspirin or placebo (group 2, 338). The measure of outcome was death from vascular disease, any stroke, myocardial infarction, or systemic embolism. During mean follow-up of 2·3 years, the annual rate of outcome events was 8% in patients assigned to anticoagulants vs 17% in placebo-treated patients in group 1 (hazard ratio [HR] 0·53; 95% confidence interval [Cl] 0·36-0·79). The risk of stroke alone was reduced from 12% to 4% per year (HR 0·34; 95% Cl 0·20-0·57). Among all patients assigned to aspirin (groups 1 and 2), the annual incidence of outcome events was 15%, against 19% in those on placebo (HR 0·83; 95% Cl 0·65-1·05). Anticoagulation was significantly more effective than aspirin (HR 0·60; 95% Cl 0·41-0·87). The incidence of major bleeding events was low, both on anticoagulation (2·8% per year) and on aspirin (0·9% per year). No intracranial bleeds were identified in patients assigned to anticoagulation. We conclude that anticoagulation is effective in reducing the risk of recurrent vascular events in NRAF patients with a recent TIA or minor ischaemic stroke. In absolute terms: 90 vascular events (mainly strokes) are prevented if 1000 patients are treated with anticoagulation for one year. Aspirin is a safe, though less effective, alternative when anticoagulation is contraindicated; it prevents 40 vascular events each year for every 1000 treated patients.

References (32)

  • The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators

    The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

    N Engl J Med

    (1990)
  • Md Ezekowitz et al.

    Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation

    N Engl J Med

    (1992)
  • Cp Warlow

    Non-rheumatic atrial fibrillation: warfarin or aspirin for all? Neurological comment

    Br Heart J

    (1992)
  • J. Weinberger et al.

    Noninvasive evaluation of the extracranial carotid arteries in patients with cerebrovascular events and atrial fibrillations

    Arch Intern Med

    (1988)
  • Ts Olsen et al.

    Cause of cerebral infarction in the carotid territory. Its relation to the size and the location of the infarct and to the underlying vascular lesion

    Stroke

    (1985)
  • Cited by (1856)

    • Factors affecting self-reported bleeding acceptance in acute ischemic stroke survivors on various types of antithrombotic therapy

      2023, Journal of Stroke and Cerebrovascular Diseases
      Citation Excerpt :

      Atrial fibrillation (AF), accounting for about 15-20% of all strokes, is associated with 5-fold greater risk of AIS.7 Oral anticoagulation (OAC) with either vitamin K antagonists (VKAs) or non-vitamin K antagonist OACs (NOACs) effectively prevents recurrence of cardioembolic stroke with a relative risk reduction of 60–70%.8 Bleeding represents the most feared adverse event of OAC or antiplatelet therapy (APT).

    • Strokelore: Therapeutic relevance of lacunar infarcts

      2022, Journal of Stroke and Cerebrovascular Diseases
    View all citing articles on Scopus
    1

    Correspondence to: Dr Peter J Koudstaal, Department of Neurology, University Hospital Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, Netherlands.

    View full text